UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 10-K/A
 
 
Amendment No. 1
 
 

ý
Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2016
 
OR
¬
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from                      to                     .
Commission file number: 000–33001
 
 
 
 NATUS MEDICAL INCORPORATED
(Exact name of Registrant as specified in its charter)
Delaware
 
77–0154833
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)
(925) 223-6700
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
 
Name of each exchange on which registered
Common Stock, $0.001 par value per share
 
The NASDAQ Stock Market LLC
(Nasdaq Global Select Market)
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ý    No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý  No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K.  ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer," "accelerated filer,” and "smaller reporting company" in Rule 12b-2 of the Exchange Act:





 
Large accelerated filer ý
 
Accelerated filer ¬
 
 
 
 
 
Non-accelerated filer ¬
 
Smaller reporting company ¬
 
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  ý
As of June 30, 2016, the last business day of Registrant’s most recently completed second fiscal quarter, there were 32,942,199 shares of Registrant’s common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 30, 2016) was $1,245,215,122. Shares of Registrant’s common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
On February 17, 2017, the registrant had 32,866,703 shares of its common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The Registrant has incorporated by reference, into Part III of this Form 10-K, portions of its Proxy Statement for the 2017 Annual Meeting of Stockholders.








EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (this "Amendment") to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, initially filed with the Securities and Exchange Commission ("SEC") on February 24, 2017 (the "Original Filing"), is being filed to amend Exhibit 23.1, the Consent of Independent Registered Public Accounting Firm.
Also included in this Amendment are (i) signature page and (ii) certifications required of the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, we are not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
No attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Original Filing or modify or update those disclosures, including the exhibits to the Original Filing, affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and our other filings made with the SEC.  

PART IV 

ITEM 15.    Exhibits, Financial Statement Schedules
(a)(3) Exhibits 
The Exhibits listed in the Index to Exhibits, which appears immediately following the signature page and is incorporated herein by reference, are filed as part of this 10-K/A.









SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized. 
 
 
 
NATUS MEDICAL INCORPORATED
 
 
By
 
/s/    JAMES B. HAWKINS        
 
 
James B. Hawkins
President and Chief Executive Officer
 
 
By
 
/s/    JONATHAN A. KENNEDY        
 
 
Jonathan A. Kennedy
Executive Vice President and Chief Financial Officer
Dated: March 2, 2017








EXHIBIT INDEX 
 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
3.1
 
Natus Medical Incorporated Amended and Restated Certificate of Incorporation
 
S-1
 
3.1.1

 
333-44138
 
8/18/2000
3.2
 
Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock
 
8-A
 
3.1.2

 
000-33001
 
9/6/2002
3.3
 
Bylaws of Natus Medical Incorporated
 
8-K
 
3.1

 
000-33001
 
6/18/2008
10.1
 
Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers
 
S-1
 
10.1

 
333-44138
 
8/18/2000
10.2*
 
Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan
 
8-K
 
10.1

 
000-33001
 
1/4/2006
10.2.1*
 
Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan
 
S-1
 
10.3.1

 
333-44138
 
8/18/2000
10.2.2*
 
Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-Q
 
10.2

 
000-33001
 
8/9/2006
10.2.3*
 
Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-K
 
10.2.3

 
000-33001
 
3/14/2008
10.3*
 
Natus Medical Incorporated 2000 Director Option Plan
 
10-Q
 
10.02

 
000-33001
 
5/9/2008
10.3.1*
 
Form of Option Agreement under the 2000 Director Option Plan
 
S-1
 
10.4.1

 
333-44138
 
8/18/2000
10.4*
 
Natus Medical Incorporated 2000 Supplemental Stock Option Plan
 
S-1
 
10.15

 
333-44138
 
2/9/2001
10.4.1*
 
Form of Option Agreement for 2000 Supplemental Stock Option Plan
 
S-1
 
10.15.1

 
333-44138
 
2/9/2001
10.5*
 
Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder
 
8-K
 
10.2

 
000-33001
 
1/4/2006
10.6*
 
[Amended] 2011 Stock Awards Plan
 
14-A
 

 
000-33001
 
4/20/2011
10.6.1*
 
Form of Stock Option Award Agreement under the [Amended] 2011 Stock Plan
 
10-Q
 
10.1

 
000-33001
 
11/7/2011
10.6.2*
 
Form of Restricted Stock Award Purchase Agreement
 
10-Q
 
10.2

 
000-33001
 
11/7/2011
10.6.3*
 
Form of Restricted Stock Unit Agreement
 
10-Q
 
10.3

 
000-33001
 
11/7/2011
10.7*
 
2011 Employee Stock Purchase Plan
 
14-A
 

 
000-33001
 
4/20/2011
10.7.1*
 
2011 Employee Stock Purchase Plan Subscription Agreement
 
14-A
 

 
000-33001
 
4/20/2011
10.8*
 
Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
10-K
 
10.10

 
000-33001
 
3/10/2009
10.8.1*
 
Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
 
 
 
 
 
 
 





 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
10.9*
 
Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013
 
8-K
 
99.1

 
000-33001
 
4/22/2013
10.10*
 
Form of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated April 8, 2013
 
10-Q
 
10.1

 
000-33001
 
8/8/2013
10.11
 
Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015
 
8-K
 
10.1

 
000-33001
 
10/9/2015
10.12
 
Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
8-K
 
 
 
000-33001
 
10/15/2015
10.13
 
Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
10-Q
 
10.2

 
000-33001
 
11/3/2016
10.14
 
Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A.
 
10-Q
 
10.1

 
000-33001
 
11/3/2016
10.15
 
Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company
 
10-Q
 
10.3

 
000-33001
 
11/3/2016
16.1
 
Letter Regarding Change in Certifying Accountant
 
8-K
 
16.1

 
000-33001
 
3/28/2014
21.1#
 
Significant Subsidiaries of the Registrant
 
 
 
 
 
 
 
 
23.1
 
Consent of Independent Registered Public Accounting Firm
 
 
 
 
 
 
 
 
24.1#
 
Power of Attorney (included on signature page)
 
 
 
 
 
 
 
 
31.1#
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
31.2#
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
31.3
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
31.4
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
32.1#
 
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
101.INS#
 
XBRL Instance Document
 
 
 
 
 
 
 
 
101.SCH#
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
101.CAL#
 
XBRL Taxonomy Extension Label Calculation Linkbase Document
 
 
 
 
 
 
 
 






 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
101.DEF#
 
XBRL Taxonomy Extension Definition Document
 
 
 
 
 
 
 
 
101.LAB#
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
101.PRE#
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 

 *    Indicates a management contract or compensatory plan or arrangement
#     Previously filed with Annual Report on Form 10-K for year ended December 31, 2016